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A 52 -year-old mu sic educator ca me to us with an 18month history of interm itten t hoarsen ess, loss of voice, an d vocal fatig ue in both his speaking and sing ing voice. He sai d that his pro blem was re late d directl y to the heavy voca l dem and s inherent in his occ upa tion. An ea rlier peri od of voice rest over the sum mer had fai led to improve his co ndition. During his office visi t, his voice was hoarse and breath y, and it had a ras py qu al ity.
Str obovid eol aryn goscopy revealed mil d to moderate ede ma of the voca l fo lds and a rig ht voc al fo ld lesion that was co nsis tent with a subepithe lia l vocal fo ld cyst. Flexible laryngoscop y dem on str ated supraglot tic hyperfunction during connected speech, whic h is ind ica tive of mu scle-t en sion dysphon ia. W e prescribed voice therapy. Foll owing co mple tion of this program, the patient was reeva luated. Strob ovideolar yngoscop y revealed a sca r that invo lved more than half ofthe memb ran ou s left voca l fold and a cyst on the right vocal fo ld.
Th e patient und erwen t a detail ed microlary ngoscopic examinatio n as we ll as pa lpa tio n of the vocal folds. Vocal fold scarring was fo und bil ater all y, as well as a sma ll right sube pithe lial mass that was beli eved to be eit he r a cys t or a fibro us mass. During microl aryn goscop y, tri am cin olon e was injec ted into the sube pithe lia l pl an e of the left vocal fold wit h a 27 -gauge nee dle.
At bo th the l-week and IO-m onth follow-up vis its, stro bovi deo laryngoscopy revealed a white, subepi the lial plaque at the site of the triamcin olon e injection (fig ure) . Th e plaqu e did not ha ve a negative imp act on the vibra tio n of the left vocal fold. However , we we re initially ala rme d by the appearance of this new lesion. Th e pa tie nt was subsequently treated wi th a fat-g raft recon stru ct ion of the left vocal fo ld and re mov al of the rig ht vocal fo ld cyst via a microfl ap approach. He d id we ll foll owing surgery and has res umed teac hing and si ng ing .
Soon thereafter , we fo und ano the r pat ie nt to have a 
Pregnancy
Teratogenic Effects. Pregnancy Category C: Reproduction studies have been perfo rmed in rats and mice using oral doses ofupto 100 mg/kgand IVdoses upto 30mg/kgand have revealed noevidence ofharm to thefetus asa result of ciprofloxacin. In rabbits, ciprofloxacin 130 and 100 mg/kg orally) produced gastroi ntestina l disturbancesresultinginmaternal weightloss and an increased incidence ofabortion,but noteratogenicitywas observed ateither dose. After intravenous administ ration ofdoses upto20mg/kg,nomaternaltoxicity was produced inthe rabbit, and noembryotoxicity orteratogenicity was observed. Corticosteroids aregenerally teratoge nic inlaboratory animals whenadministeredsystemicallyatrelativel ylowdosage levels. The morepotent corticosteroidshave beenshowntobeteratogenic after der mal application inlaboratoryanimals. Anima l reproduction studies have not beenconductedwithCIPROOEX' Otic. Noadequate and well controlled studies have been performed in pregnant women. Caution should be exe rcised when CIPROOEX' Otic isused bya pregnant woman. Nur sing Moth ers:Ciprofloxacinand corticosteroids, asa class, appear inmilk followi ng oral administration. Dexamethasoneinbreast milk could suppress growth, interferewith endogenous corticosteroidproduction, or cause otheruntowardeffects. It isnot knownwhether topica l otic administration ofciprofloxacinor dexamethasonecould result insufficient systemic abso rption toproduce detectable quantitiesinhuman milk.
Because ofthe potential for unwanted effects innursing infants, adecision should bemade whethe rto discontinue nursing ortodiscontinue the drug, takinginto account theimportance ofthe drug tothe mother. Pedi atric Use: The safety and efficacy of CIPR OOEX' Otic have been established in pediatric pat ients 6 months and older 1937pat ients) inadequate and well-controlledclinical trials. Although nodata areavai lable on patients less than age 6 months, the re are no known safety concerns or differences in the disease process inthispopulationthat woul d precludeuseofthisproduct.ISee DOSAGE AND ADMINISTRATION.) Nocli nically relevant changes inheari ngfunctionwere observed in69pediatric patients (age 4to 12years) treated withCI PROOEX' Otic and testedfor audiometric parameters. Ciprofloxacin,af1uoroquinoloneisavailableasthemonohydrochloridemonohydratesalt of 1-cyclopropyl-6fluoro-l ,4-dihydro-4-oxo-7-(I-piperazinyl)-3-quinolinecarboxylic acid. The empirical formu la is C1 7H18FN30J-HCI·H20. Dexamethasone, 9-f1uoro-l 1( beta). 17,21-trihydroxy-16(alpha)-methylpregna -1,4diene-3,20-dione, is an anti-inflammatory corticosteroi d.The empirical formulais C22H29F05.
ADVERSE REACTIONS
CLINICAL PHARMACOLOGY Pharmacokinet ics: Following a single bilateral 4-drop (total dose =0.28 ml, 0.84 mg ciprofloxacin, 0.28 mg dexam ethasone) topical otic dose of CIPROO EX' Otic to pediatric patients after tympanostomy tube insertion,measurable plasma concentrat ionsofcip rofloxacin and dexamethasone were observed at6hoursfollowingadministrat ionin2of 9 patients and5of 9patients, respectively. Mean ± SOpeak pl asm a concentrations of ciprofloxacin were 1.39 ± 0.880nglmlln; 9). Peak plasma concentrations ranged from0.54 3nglml to3.45ng/ml andwereonaverage approximately 0.1%ofpeak plasma conce ntrations achievedwith an oral dose of250-mg I1l similar "triamcinolo ne plaqu e," and we we re advised of a third case by R.T . Sa ta loff, MD (ora l co mmun ica tion, 1999). Sin ce then, we have switched fro m usi ng triamci nolone to high-concent ration (10 mg/ ml) dexamethaso ne whe n injec ting a ste ro id into the voca l fo lds . Dexameth asone so lution is clea r and does not leave any residual dep osit. Th e triam cinolone plaqu e is be lieved to be the res ult of the chalky mater ial present in the triam cinolone so lution itse lf. Tre atm en t of voca l fo ld scaring includes bo th surgical and non sur gi cal reh abilitation .I Th e initia l treatm ent of dysph on ia ass oc iated with vocal fold sca rring sho uld be nonsu rgical. Patients with dysph on ia seconda ry to vocal fold sca rring ofte n dem on strate an assoc iated co mpensatory muscle-tension dysph oni a (seconda ry) . Several dif-fere nt vocal fo ld injection meth od s have been advocated for the treatm ent of voca l fo ld scars, including steroi d injectio n int o the lam ina propria. Th ere have been reports that stero id inj ections improve vocal fold suppleness, vocal fold closur e, and voice q uality.' although success has not been co nsis tent. Wh en thi s techni que is used , the ste roid chose n sho uld be aqueo us and sho uld not co ntain components that ca n form a precipitate. 
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